AZNAstraZenecaRunning, no new patients
Study of AZD5305 When Given in Combination With New Hormonal Agents in Patients With Metastatic Prostate Cancer
Metastatic Prostate Cancer
0Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 1/2
- Patients
- 174 (final count)
- Started
- Jun 2, 2022
- Main results expected
- Apr 11, 2031
- Fully finished
- Apr 11, 2031
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Number of patients with Adverse Events and Serious Adverse Events
Measured over: Up to post treatment follow-up (28 days after last dose) [assessed up to 2.3 years]
Part A: Number of patients with Dose Limiting Toxicities (DLTs)
Measured over: For Arm 1: 35 days, For Arm 2 and 3: 28 days
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT05367440 · record last updated 2026-08-26 · checked 2026-11-09 15:47 UTC